Monopar Therapeutics (MNPR) Cash from Financing Activities (2017 - 2025)
Quarterly results put Cash from Financing Activities at -$384680.0 for Q4 2025, down 100.69% from a year ago — trailing twelve months through Dec 2025 was $91.6 million (up 54.45% YoY), and the annual figure for FY2025 was $91.6 million, up 54.45%.
Monopar Therapeutics has reported Cash from Financing Activities over the past 9 years, most recently at -$384680.0 for Q4 2025.
- Cash from Financing Activities reached -$384680.0 in Q4 2025 per MNPR's latest filing, down from $92.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $92.4 million in Q3 2025 and bottomed at -$384680.0 in Q4 2025.
- Median Cash from Financing Activities over the past 5 years was -$8845.5 (2021), compared with a mean of $8.2 million.
- Peak annual rise in Cash from Financing Activities hit 558897.68% in 2025, while the deepest fall reached 3094.32% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$7772.0 in 2021, then skyrocketed by 1885.09% to $138737.0 in 2022, then surged by 141.14% to $334548.0 in 2023, then surged by 16679.9% to $56.1 million in 2024, then crashed by 100.69% to -$384680.0 in 2025.
- Business Quant data shows Cash from Financing Activities for MNPR at -$384680.0 in Q4 2025, $92.4 million in Q3 2025, and -$316845.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - | -384,680.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -384,680.00 |
| Dec 31, 2025 | -384,680.00 |
| Sep 30, 2025 | 92.39 Mn |
| Sep 30, 2025 | 92.39 Mn |
| Jun 30, 2025 | -316,845.00 |
| Jun 30, 2025 | -316,845.00 |
| Mar 31, 2025 | -115,682.00 |
| Mar 31, 2025 | -115,682.00 |
| Dec 31, 2024 | 56.14 Mn |
| Dec 31, 2024 | 56.14 Mn |
| Sep 30, 2024 | -16,534.00 |
| Sep 30, 2024 | -16,534.00 |
| Jun 30, 2024 | -9,919.00 |
| Jun 30, 2024 | -9,919.00 |
| Mar 31, 2024 | 3.18 Mn |
| Mar 31, 2024 | 3.18 Mn |
| Dec 31, 2023 | 334,548.00 |
| Dec 31, 2023 | 334,548.00 |
| Sep 30, 2023 | 246,703.00 |
| Sep 30, 2023 | 246,703.00 |
| Jun 30, 2023 | 641,178.00 |
| Jun 30, 2023 | 641,178.00 |
| Mar 31, 2023 | 804,798.00 |
| Mar 31, 2023 | 804,798.00 |
| Dec 31, 2022 | 138,737.00 |
| Dec 31, 2022 | 138,737.00 |
| Sep 30, 2022 | -23,738.00 |
| Sep 30, 2022 | -23,738.00 |
| Jun 30, 2022 | -65,460.00 |
| Jun 30, 2022 | -65,460.00 |
| Mar 31, 2022 | -16,666.00 |
| Mar 31, 2022 | -16,666.00 |
| Dec 31, 2021 | -7,772.00 |
| Dec 31, 2021 | -7,772.00 |
| Sep 30, 2021 | -9,978.00 |
| Sep 30, 2021 | -9,978.00 |
| Jun 30, 2021 | -24,003.00 |
| Jun 30, 2021 | -24,003.00 |
| Mar 31, 2021 | 10.92 Mn |
| Mar 31, 2021 | 10.92 Mn |
| Dec 31, 2020 | -7,140.00 |
| Dec 31, 2020 | -7,140.00 |
| Sep 30, 2020 | 6.73 Mn |
| Sep 30, 2020 | 6.73 Mn |
| Jun 30, 2020 | 946,404.00 |
| Jun 30, 2020 | 946,404.00 |
| Mar 31, 2020 | 508,044.00 |
| Mar 31, 2020 | 508,044.00 |
| Dec 31, 2019 | 9.39 Mn |
| Dec 31, 2019 | 9.39 Mn |
| Sep 30, 2019 | -13,281.00 |
| Sep 30, 2019 | -13,281.00 |
| Jun 30, 2019 | -12,322.00 |
| Jun 30, 2019 | -12,322.00 |
| Mar 31, 2019 | -13,855.00 |
| Mar 31, 2019 | -13,855.00 |
| Dec 31, 2018 | -206,270.00 |
| Dec 31, 2018 | -206,270.00 |
| Dec 31, 2017 | 10,001.00 |
| Dec 31, 2017 | 10,001.00 |
| Sep 30, 2017 | 7.50 Mn |
| Sep 30, 2017 | 7.50 Mn |
| Jun 30, 2017 | 1.04 Mn |
| Jun 30, 2017 | 1.04 Mn |
| Mar 31, 2017 | 990,002.00 |
| Mar 31, 2017 | 990,002.00 |